Camrelizumab: an investigational agent for hepatocellular carcinoma

Xu, B; Sun, HC

Sun, HC (通讯作者),Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg & Transplantat, 180 Fenglin Rd, Shanghai 200032, Peoples R China.

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022; 31 (4): 337

Abstract

Introduction Although many approaches have been used to treat hepatocellular carcinoma (HCC), the clinical benefits were limited, particularly for adv......

Full Text Link